DnB Asset Management Portfolio holdings
AUM
$24.1B
1-Year Return
22.48%
This Quarter Return
+14.89%
1 Year Return
+22.48%
3 Year Return
+110.52%
5 Year Return
+180.23%
10 Year Return
+394.81%
AUM
$19.2B
AUM Growth
-$83.7M
(-0.43%)
Cap. Flow
-$2.37B
Cap. Flow
% of AUM
-12.37%
Top 10 Holdings %
Top 10 Hldgs %
40.05%
Holding
730
New
85
Increased
159
Reduced
458
Closed
25
Top Buys
| 1 |
Western Digital
WDC
|
$141M |
| 2 |
HP
HPQ
|
$130M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
$108M |
| 4 |
Micron Technology
MU
|
$94.7M |
| 5 |
TSMC
TSM
|
$70.6M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$443M |
| 2 |
Microsoft
MSFT
|
$316M |
| 3 |
Meta Platforms (Facebook)
META
|
$240M |
| 4 |
Apple
AAPL
|
$115M |
| 5 |
Electronic Arts
EA
|
$90.9M |
Sector Composition
| 1 | Technology | 34.8% |
| 2 | Communication Services | 18.17% |
| 3 | Financials | 12.56% |
| 4 | Healthcare | 9.34% |
| 5 | Consumer Discretionary | 7.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
626
SentinelOne
S
$6.25B
| $416K | ﹤0.01% |
+17,840
| New | +$416K |
|
|
MTTR
627
DELISTED
Matterport, Inc. Class A Common Stock
MTTR
| $415K | ﹤0.01% |
+183,619
| New | +$415K |
|
628
Navitas Semiconductor
NVTS
$1.19B
| $414K | ﹤0.01% |
86,864
+2,668
| +3% | +$12.7K |
|
629
Archer Aviation
ACHR
$5.48B
| $412K | ﹤0.01% |
89,144
-50,254
| -36% | -$232K |
|
630
Krystal Biotech
KRYS
$4.35B
| $409K | ﹤0.01% |
+2,300
| New | +$409K |
|
631
Rocket Lab Corporation Common Stock
RKLB
$22.1B
| $399K | ﹤0.01% |
97,359
-44,750
| -31% | -$183K |
|
632
Joby Aviation
JOBY
$11.5B
| $393K | ﹤0.01% |
73,402
-7,069
| -9% | -$37.9K |
|
633
Apellis Pharmaceuticals
APLS
$3.55B
| $357K | ﹤0.01% |
+6,068
| New | +$357K |
|
634
Axsome Therapeutics
AXSM
$6.25B
| $353K | ﹤0.01% |
+4,426
| New | +$353K |
|
635
Immunocore
IMCR
$1.87B
| $347K | ﹤0.01% |
+5,343
| New | +$347K |
|
636
Aurora
AUR
$10.6B
| $339K | ﹤0.01% |
120,103
-91,687
| -43% | -$259K |
|
637
Transmedics
TMDX
$3.55B
| $334K | ﹤0.01% |
+4,516
| New | +$334K |
|
638
Amicus Therapeutics
FOLD
$2.46B
| $318K | ﹤0.01% |
27,018
+2,182
| +9% | +$25.7K |
|
639
Immunovant
IMVT
$2.99B
| $302K | ﹤0.01% |
+9,332
| New | +$302K |
|
640
Stem
STEM
$117M
| $287K | ﹤0.01% |
6,546
+218
| +3% | +$9.55K |
|
641
MoonLake Immunotherapeutics
MLTX
$3.77B
| $285K | ﹤0.01% |
+5,678
| New | +$285K |
|
642
Scholar Rock
SRRK
$3.02B
| $274K | ﹤0.01% |
+15,422
| New | +$274K |
|
643
Hims & Hers Health
HIMS
$10.9B
| $271K | ﹤0.01% |
+17,493
| New | +$271K |
|
644
Zurn Elkay Water Solutions
ZWS
$7.71B
| $260K | ﹤0.01% |
+7,781
| New | +$260K |
|
645
Annexon
ANNX
$238M
| $257K | ﹤0.01% |
+35,911
| New | +$257K |
|
646
Legend Biotech
LEGN
$6.66B
| $257K | ﹤0.01% |
+4,589
| New | +$257K |
|
647
Kanzhun
BZ
$11.1B
| $253K | ﹤0.01% |
14,421
+1,951
| +16% | +$34.2K |
|
648
Iovance Biotherapeutics
IOVA
$901M
| $251K | ﹤0.01% |
+16,931
| New | +$251K |
|
|
RVNC
649
DELISTED
Revance Therapeutics, Inc.
RVNC
| $236K | ﹤0.01% |
48,028
+13,376
| +39% | +$65.7K |
|
650
4D Molecular Therapeutics
FDMT
$340M
| $234K | ﹤0.01% |
+7,363
| New | +$234K |
|